Heartflow (NASDAQ:HTFL) Director Jeffrey Lightcap Buys 40,000 Shares

Heartflow, Inc. (NASDAQ:HTFL) Director Jeffrey Lightcap purchased 40,000 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were acquired at an average cost of $26.34 per share, for a total transaction of $1,053,600.00. Following the completion of the acquisition, the director owned 40,000 shares of the company’s stock, valued at approximately $1,053,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Heartflow Price Performance

NASDAQ HTFL opened at $26.69 on Thursday. The stock has a 50-day simple moving average of $32.06. Heartflow, Inc. has a twelve month low of $25.38 and a twelve month high of $41.22.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Friday, September 19th. The company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.26). The company had revenue of $43.42 million during the quarter, compared to the consensus estimate of $43.20 million.

Institutional Investors Weigh In On Heartflow

Hedge funds and other institutional investors have recently made changes to their positions in the company. Hudson Bay Capital Management LP purchased a new position in shares of Heartflow during the 3rd quarter worth about $288,000. XXEC Inc. purchased a new stake in Heartflow in the 3rd quarter worth about $1,004,000. Zimmer Partners LP purchased a new position in shares of Heartflow during the third quarter valued at approximately $673,000. Alyeska Investment Group L.P. bought a new position in shares of Heartflow during the third quarter valued at approximately $2,861,000. Finally, Summit Partners Public Asset Management LLC purchased a new stake in shares of Heartflow in the third quarter worth approximately $28,559,000.

Wall Street Analyst Weigh In

HTFL has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday. Zacks Research upgraded Heartflow to a “hold” rating in a research report on Wednesday, September 3rd. Piper Sandler initiated coverage on Heartflow in a research report on Tuesday, September 2nd. They issued an “overweight” rating and a $38.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Finally, Canaccord Genuity Group lifted their price objective on Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $38.60.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.